San Diego—Two therapies that once appeared promising for recurrent ovarian cancer—cabozantinib and an oncolytic reovirus—have struck out, according to research reported at the 2016 annual meeting of the Society of Gynecologic Oncology (SGO).
David Cohn, MD, the director of the Division of Gynecologic Oncology at Ohio State University College of Medicine, in Columbus, presented results from a randomized Phase IIb trial evaluating the addition of an oncolytic reovirus to weekly